Compare Stanley Black & Decker, Inc. (SWK) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stanley Black & Decker, Inc. vs BIO-TECHNE Corp — how do they compare? Stanley Black & Decker, Inc. trades at $89.66 (market cap $13.34B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Stanley Black & Decker, Inc. is the larger of the two by market cap, and Stanley Black & Decker, Inc. pays the higher dividend (3.8%). Which is the better fit depends on your goals — on Pluang, investors hold Stanley Black & Decker, Inc. for 62 Days and BIO-TECHNE Corp for 63 Days on average.
| SWK | TECH | |
|---|---|---|
Market Cap | $13.34B | $11.37B |
Volume | 1,609,355 | 3,153,511 |
Sector | Industrials | Health |
52-Week High | $104.00 | $72.61 |
52-Week Low | $62.12 | $43.31 |
Typical Hold Time | 62 Days | 63 Days |
Enterprise Value | $17.50B | $11.40B |
Dividend Yield | 3.8% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stanley Black & Decker (SWK) trades at $89.17, down 0.91% on the day, with a bearish technical signal from moving averages and oscillators. The company has beaten earnings estimates in recent quarters, with Q3 2026 results expected on November 4, 2026. Financials show improving net income margins, from 1.91% in 2024 to 2.65% in 2025, supported by strong cash flow from operations of $971.20 million in 2025. Recent news highlights product launches like the dustbuster® mini™ and management's focus on margin gains.
SWK presents a mixed outlook with a consensus price target of $93.00 implying modest upside. Strengths include a solid dividend history and earnings beats, but risks involve persistent bearish technical indicators and competitive pressures. The stock's valuation metrics, such as a P/E of 21.59 and P/S of 0.88, suggest reasonable pricing relative to peers, though investor sentiment remains cautious amid macroeconomic uncertainties.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
